Background. The genotoxicity of zidovudine has been established in experimental models. The objective of the study was to identify genotoxicity markers in cord blood cells from newborns exposed in utero to antiretroviral (ARV) combinations containing zidovudine.
The prevention of human immunodeficiency virus type 1 (HIV-1) transmission from mother to child by the administration of antiretrovirals (ARVs) during pregnancy is remarkably effective. The risk of transmission to the child is now <1%, provided that maternal viral replication is suppressed for several weeks before delivery [1] . A worldwide program of virtual elimination of motherto-child transmission of HIV-1 is being implemented through the administration of ARVs to the largest possible number of HIV-1-infected pregnant women [2] . Current recommendations are based on the use of a combination of 3 ARVs [1] . However, in all guidelines, zidovudine remains the reference drug for mother-to-child prophylaxis, except for cases in which another ARV combination was already being administered prior to pregnancy [3, 4] . This position contrasts with the gradual decrease of zidovudine use as a first-line treatment for adults, at least in high-resource countries [5] . Fetal and neonatal tolerance of zidovudine has been discussed ever since this drug was first used during pregnancy, because of its transplacental transfer [6] and its established affinity for human DNA [7, 8] . The most common clinical toxicity observed in the newborn after exposure to zidovudine in utero is a moderate and transient macrocytic anemia [9] . Subsequent analysis of hematological markers in 3 large cohorts revealed small but significant decreases in neutrophil and lymphocyte counts up to 8 years of age [10] [11] [12] [13] [14] . These findings are consistent with zidovudine inducing persistent alterations of the hematopoietic stem cell (HSC) compartment. The first evaluations of the zidovudine-DNA interactions in exposed newborns focused on mitochondrial DNA, following observations of neurological symptoms associated with mitochondrial dysfunction [15] . Initially contested, this mitochondrial toxicity is now recognized [16] , although the entire spectrum of clinical expression and its long-term effects remain to be established [17] . There is now substantial experimental evidence for the effects of zidovudine on nuclear DNA, and its integration into the DNA of human newborns after exposure in utero has been demonstrated [18] . The genotoxicity of zidovudine in experiment models is such that the drug is considered as a possible human carcinogen (class 2B) by the International Agency For Research on Cancer [7] . Nevertheless, the molecular and cytogenetic consequences of exposure to zidovudine prophylaxis have not been evaluated [18] [19] [20] [21] . The aim of our study was to search for genotoxic biological signatures in cord blood cells from HIV-1-uninfected children exposed to zidovudine-based ARV in utero and to test for any specific effects of the drug on hematopoietic stem/progenitor cells (HPCs).
PATIENTS AND METHODS

Patients
The study was proposed to HIV-1-infected and noninfected pregnant women in 5 maternity hospitals in the Paris area after they had provided written informed consent. The protocol consisted of collecting placental blood at birth, just before placental delivery. For HIV-1-infected women to be eligible, they must have received a zidovudine-based ARV combination for at least 4 weeks before delivery and no additional treatment other than standard supplements during pregnancy. Only women with uncomplicated pregnancies and no chronic pathology, other than HIV-1 infection, were enrolled. The noninfected status of all infants born to HIV-1-infected women was established by findings of at least 2 polymerase chain reaction (PCR) tests for HIV-1 RNA, one being performed after 1 month of age. Participation in the study had no influence on the choice of the HIV-1 prophylactic regimen, the mode of delivery, or the subsequent monitoring of the child, which were selected by the clinicians according to national guidelines. To constitute a control group of non-ARV-exposed newborns, the protocol was proposed to healthy pregnant women without HIV-1 infection, who were followed in the same centers. No clinical or laboratory followup was required for these newborns.
Cord Blood Sampling and Cell Preparation
Cord blood was collected by the obstetrician or midwife during the third stage of labor, just before placental delivery. After the child was delivered, the umbilical cord was clamped, sectioned, and disinfected. The umbilical vein was punctured, and the largest possible volume of blood was collected by gravity into a bag containing citrate as an anticoagulant. Mononuclear cells were separated out, and the CD34 + cell fraction (<0.5% of cord blood mononuclear cells) was magnetically sorted as previously described [22] . The CD34 + and CD34 − cell fractions were both cryopreserved until the HIV-1 RNA PCR results were available.
Cytogenetics
Chromosomal preparations were obtained from PHA-stimulated CD34 − cell fractions by using standard procedures after 72 hours of culture. Chromosomal preparations were subjected to Giemsa reverse banding and were karyotyped according to 2009 International System for Human Cytogenetic Nomenclature recommendations [23] . At least 30 well-spread metaphases were scored for each case.
Immunophenotyping of Hematopoietic Cell Compartment
The hematopoietic progenitor content of cord blood was determined by flow cytometry, on the basis of CD34 and CD45 coexpression. Cluster analysis was carried out using probe sets reannotated with custom definition files, to ensure unequivocal probe-to-gene assignment [26, 27] . Differentially expressed genes were identified using DNA-Chip Analyzer software (dChip; available at: http://www.dchip.org) by selecting transcripts for which the difference in the level of expression between the 2 groups yielded a P value of .01 in a supervised analysis. Gene set enrichment analysis was performed with GSEA software (available at: http://www.broadinstitute.org/gsea/index. jsp), using the Reactome pathways derived from the Molecular Signatures Database (available at: http://www.broadinstitute. org/gsea/msigdb/index.jsp). Signatures were considered to be significantly enriched at a false-discovery rate q value of < 0.01. The microarray data have been made available through the National Center for Biotechnology Information Gene Expression Omnibus database.
Statistical Analysis
For analyses other than those involving transcriptional profiling, Fisher exact tests (for categorical variables) and Wilcoxon tests (for continuous variables) were used to compare baseline characteristics and outcomes between the ARV-exposed and control groups of newborns. Potential correlations between variables were tested with the Spearman correlation coefficients test. P < .05 was used as the threshold for statistical significance. SAS software, version 9.2 (SAS Institute, Cary, NC), was used.
Ethical Issues
The protocol was reviewed and approved by the regional institutional review board (Comité de Protection des Personnes, CPP Paris-Ile de France) in accordance with French legislation and ethical guidelines.
RESULTS
Patient and Control Characteristics
Cord blood was collected from 15 HIV-1-infected women and 12 control women ( Table 1 ). All newborns born to infected mothers were uninfected on the basis of repeated HIV-1 RNA PCR testing. The characteristics of the HIV-1-infected women and their uninfected newborn were unremarkable and consistent with those of the nationwide epidemiological cohort over the same period (data not shown). No mothers were addicted to drugs, and all had been infected by the sexual route. All HIV-1-infected mothers were given zidovudine associated with another nucleoside analogue (lamivudine for all but one of the mothers, didanosine for the other) and a ritonavir-boosted protease inhibitor (lopinavir in 13 cases, atazanavir in 2 cases). The median duration of ARV treatment during pregnancy was 31 weeks (interquartile range [IQR], 17-38 weeks). As expected, Abbreviations: ARV, antiretroviral; ATV, atazanavir; AZT, zidovudine; ddI, didanosine; LPV/r, ritonavir-boosted lopinavir; 3TC, lamivudine. a Including AZT-3TC-ATV/r (n = 2) and AZT-ddI-LPV/r (n = 1).
b Cumulative incidence according to AIDS Clinical Trials Group grading criteria, adapted for birth and 1 and 3 months of age.
HIV-1-infected mothers delivered by cesarean section more frequently than controls and had a 2-week difference in term at delivery. There was no significant difference concening maternal age or newborn weight between the 2 groups. No clinical event was reported for the infants born to HIV-1-infected mothers. The median hemoglobin concentration at birth for children exposed to zidovudine was 16.1 g/dL (IQR, 13-17.4 g/ dL), without any newborn displaying grade ≥II anemia as defined by the AIDS Clinical Trials Group.
Cord Blood Collected
The median volume of umbilical cord blood collected ( P = .43) were similar between ARV-exposed newborns and controls, respectively.
Cytogenetic Study
Karyotyping was performed on the CD34 − fraction from 15 ARV-exposed newborns and 12 controls. The proportion of aneuploid cells was higher in ARV-exposed samples, in which the median value was 18.8% (IQR, 10.0%-26.7%), compared with 6.6% (IQR, 3.1%-11.7%) in control samples (P < .001; Figure 1A and 1B). All chromosomes were involved, with a random distribution of the alterations. Losses of chromosomes (hypodiploidy) were more frequent than gains without chromosome recurrence. One ARV-exposed sample differed from all the others in that endoreplicative metaphases (tetraploidy) were observed in 18 of the 30 cells analyzed. There was no link between the duration of ARV exposure during pregnancy and aneuploidy rate (Spearman correlation coefficient, −0.04; P = .88).
Gene Expression Profiling of CD34 + HPCs
Because zidovudine displays specific hematological toxicity, the were not available at the time of selection but retrospectively showed a similar difference as that observed for the samples as a whole (median, 22.6% in the ARV-exposed group vs 6.45% for controls). Unsupervised hierarchical clustering by the dChip software showed a tendency to cluster in 2 main branches corresponding to ARV-exposed and control samples, indicating that ARV exposure was associated with consistent changes in the gene expression profile of the CD34 + cells. A supervised clustering approach identified 213 upregulated and 90 downregulated genes in the ARV-exposed cells with a foldchange >1.5 (P < .05; Figure 2) ; a complete list of deregulated genes is given in Supplementary Table 1 . Over 37% of a random sample of 19 differentially expressed genes was confirmed by a quantitative PCR validation assay (data not shown) Figure 1 . Aneuploidy in CD34 -cells. Chromosomal preparations were obtained from the PHA-stimulated CD34 -cell fraction after 72 hours of culture. At least 30 well-spread metaphases were scored for each sample. A, The aneuploidy rate was determined as the percentage of all scored cells that were aneuploid for each antiretroviral (ARV)-exposed and control sample. Bars represent medians. The aneuploidy rate was significantly higher in ARV-exposed samples, compared with control samples (P < .001). B, Representative image of aneuploid mitosis.
as being significantly differentially expressed between the 2 samples (P < .1).
To explore the molecular pathways significantly affected in ARV-exposed cells, we used GSEA software and the REAC-TOME gene sets to test for statistically significant associations between gene signatures and the ARV-treated cell subset. The top-ranking pathways included cell signaling (6 gene sets), hemostasis (5 gene sets), cell cycle control (5 gene sets), and transcription (2 gene sets; false-discovery rate q value, < 0.05; Table 2 ). Ingenuity functional clustering analysis of the list of differentially expressed genes gave similar results (Supplementary Figure 1) . These analyses indicated significant overrepresentation among the deregulated genes in the following categories: cellular growth and proliferation; cell cycle; DNA replication, recombination, and repair; and cell death. The GSEA and ingenuity analysis both revealed significant deregulation of cell cycle pathways, and the corresponding affected genes included BUB1B, CCNE1, CCNE2, CDK1, KNTC1, and ORC6 (Figure 3) . The second most affected pathway was DNA recombination, replication, and repair, and the corresponding genes included BLM, WRN, ERCC4, SUPV3L1, and FAM175A.
DISCUSSION
We report that there were 3 times more aneuploid cells in cord blood from children exposed in utero to zidovudine-based Figure 2 . Gene expression profile in CD34 + cells. Affymetrix analysis of the gene expression profiles of CD34 + cells from antiretroviral (ARV)-exposed (A) and control (C) groups. Significant differences are based on a 1.5-fold difference and a P value of <.05.
ARV combinations than in that from control newborns. Aneuploidy occurs during cell division, when the chromosomes do not separate properly between the 2 cells, which then contain abnormal numbers of chromosomes. Few errors occur during normal mitosis, but external perturbations, such as exposure to genotoxic agents, can increase the rate of aneuploidy [28] . Aneuploidy and the detection of micronuclei containing lost chromosome(s) are widely used, both in vitro and in vivo, as markers of genotoxicity [29] . Although maternal HIV infection itself has been found to be associated with several biological perturbations in uninfected newborns [30] , experimental data evidencing the cellular and animal toxicity of zidovudine suggest that it may have been directly responsible for the aneuploidy described in this study. Zidovudine-induced aneuploidy has been observed in several experimental cell lines, including Chinese hamster ovary cells, human mammary epithelial cells, human lymphoblastoid MOLT-3 cells, and murine embryonic stem cells [31] [32] [33] . The Erythrocebus patas monkey model developed by Miriam Poirier and Ofelia Olivero (National Cancer Institute, National Institutes of Health) is more representative of human newborn exposure to zidovudine [34] . After exposure to human-equivalent doses of zidovudine during gestation, abnormal and durable chromosome segregation was observed in fetal bone marrow mesenchymal cells, with an aneuploidy rate 5-7-fold higher than for controls [35] . Zidovudine is a thymidine analogue with affinity for human DNA; it is incorporated into the DNA and acts as a DNA chain terminator [7, 8] . In cultured cells, the presence of zidovudine is associated with genomic instability due to the generation of single-strand DNA gaps and double-strand DNA breaks [36] . It was recently shown that zidovudine is mutagenic for template-switchgenerated genetic mutations [37] . Despite the nucleotide excision repair process [38] , zidovudine causes cell cycle arrest, sister chromatid exchange, centrosome amplification, and telomere shortening [39] . Finally, our data are also consistent with the observation of a higher frequency of erythrocyte micronuclei in a small group of human infants exposed in utero to zidovudine than in children born to HIV-infected mothers not treated with ARV [20] . The protease inhibitors (lopinavir or atazanavir) included in the ARV combinations administered to women in this study are not known to induce DNA alteration. However, lamivudine, a cytidine analogue, can induce a clastogenic effect and micronuclei phenomena in vitro [40] . In many experimental models of genotoxicity and in clinical practice, lamivudine acts synergistically with zidovudine [41] . Both drugs cross the placenta and become concentrated in the amniotic fluid at up to 1000% of the concentration in the maternal circulation [6] . The aneuploidy rate does not appear to be linked to the duration of in utero exposure. However, this finding deserves further analysis because of the small number of cord blood samples tested and the similar durations of treatment in these women.
Zidovudine has long-lasting effects on various hematopoietic lineages. We therefore tested for detect DNA damage in cord blood hematopoietic CD34 + HPCs. Cord blood from children exposed in utero to zidovudine-based ARV combinations exhibited quantitative alterations affecting the most immature hematopoietic compartment; the HSC and MPP content was higher in cord blood from ARV-exposed samples than in that from unexposed controls. The numbers of CD34 + cells recovered from cord blood were too low to allow similar cytogenetic analysis by karyotyping. Nevertheless, we describe alterations in the gene expression profile of HPCs from newborns exposed to ARV that are compatible with an alteration of the cell cycle and, in particular, with alterations of the expression of genes regulating chromosomal stability/instability and the DNA damage response [42] . Transcriptome analysis implicated a number of genes involved in centrosome amplification (CCNE2), mitotic Data were analyzed by GSEA software with the REACTOME gene sets from the Molecular Signatures Database.
Abbreviations: ATR, ataxia-telangiectasia mutated and Rad3-related; FDR, falsediscovery rate; NES, normalized enrichment score; TLR, Toll-like receptor.
checkpoint defects (BUB1B and KNTC1), the cell cycle (CCNE1, CCNE2, and CDK1), and DNA repair (BLM and WRN). We also observed strong upregulation of genes involved in microtubule attachment and chromosome segregation, including TUBB1 and TUBGCP5. These major cell cycle regulators guard against chromosome missegregation and the subsequent production of aneuploid daughter cells [43, 44] . These findings thus appear to be entirely coherent with the increased aneuploidy rate. The role of each of the 3 drugs is more difficult to assess from the results of the transcriptome analysis. However, 42 of the genes we identified as being abnormally expressed in HPCs have also been found to be abnormally expressed in mammary epithelial cells treated in vitro with zidovudine; these genes include BUB1B, CDK1, CCNE2, ORC6, TUBGCP5, and TTI1 (O. Olivero, personal communication) [39] . Human HSCs respond to DNA damage by various mechanisms: unlike more committed progenitors, the default program for damaged HSCs is to undergo apoptosis. However, human HSCs can be rescued from apoptosis by regulation of expression of transcription factors that are key in the cell cycle and in cell death or by antiapoptotic proteins [45] [46] [47] [48] . The abnormally high counts of circulating HSCs and MPPs in cord blood of ARVexposed neonates suggest that this HPC compartment attempts to compensate for drug toxicity by increasing proliferation, as also observed in the context of chemotherapy-induced toxicity. The long-term consequences of stem cell alterations may include decreased self-renewal capacities and hematopoietic impairment, as well as malignant transformation. Whether whole-chromosome aneuploidy contributes to tumorigenesis is still the subject of debate. A recent study found that chromosomes within the micronuclei become damaged during the S phase, owing to abnormal replication and an impaired DNA damage response [49] . These chromosomes become highly fragmented, and the broken, damaged pieces can be reincorporated into the main genome during mitosis, causing various DNA lesions. This work also suggests that fragmented chromosomes acquire multiple cancercausing mutations in a single event as a result of their imperfect reassembly.
The few published studies addressing the incidence of cancer in children exposed in utero to zidovudine do not provide evidence of a higher risk than that in the general population [50] . However, the mean follow-up of exposed children in these studies is relatively short, and the long-term risks remain unknown. Note that other cells may also be subject to zidovudine-associated DNA damage and aneuploidy. Indeed, in the previously discussed monkey model, aneuploidy affected mesenchymal cells [35] . There is now a clear evidence that tight control of virus replication is the key to preventing mother-to-child HIV-1 transmission; prevention is not specifically dependent on zidovudine. The genotoxicity profiles of other ARV drugs, and particularly nucleoside analogues, during pregnancy should be determined comparatively to identify the safest combination.
Newly available biological tools are likely to be informative about the "biological signature" left on the newborn by treatments taken by the mother, as is the case for the transcriptome analyses we describe.
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